Form 4 Filing for BioNTech SE

Sahin Ugur, Chief Executive Officer and 10% owner of BioNTech SE, reported the sale of 30,000 ordinary shares on September 23, 2026, for $99.40 per share, and 39,000 ordinary shares on September 24, 2026, for $98.99 per share. These transactions were executed under a Rule 10b5-1 trading plan. Following these sales, Mr. Ugur directly owns 341,209 ordinary shares. Additionally, he indirectly owns 39,218,111 ordinary shares through Medine GmbH, of which he is the sole shareholder. A portion of these indirectly held shares are subject to a trust arrangement, affecting only voting power, not dispositive power.